Michael Dickinson Selected Research

axicabtagene ciloleucel

1/2024	Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
12/2023	An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.
10/2023	Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
7/2023	Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
1/2023	Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
1/2022	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
1/2022	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Dickinson Research Topics

Disease

23	Neoplasms (Cancer) 04/2024 - 10/2009
15	Lymphoma (Lymphomas) 04/2024 - 10/2012
14	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2024 - 03/2006
10	B-Cell Lymphoma (Lymphoma, B Cell) 12/2023 - 01/2021
9	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2023 - 07/2010
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2024 - 11/2014
7	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2023 - 05/2012
6	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2023 - 10/2009
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 09/2013
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2024 - 02/2023
4	Infections 12/2023 - 01/2017
4	Multiple Myeloma 01/2023 - 12/2011
4	Febrile Neutropenia 11/2021 - 02/2013
4	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 10/2020 - 08/2013
3	COVID-19 12/2023 - 01/2020
3	Thrombocytopenia (Thrombopenia) 08/2023 - 12/2018
3	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 10/2009
3	T-Cell Lymphoma (Lymphoma, T Cell) 01/2021 - 08/2013
2	cell-associated neurotoxicity 12/2023 - 10/2022
2	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 10/2022
2	Diarrhea 11/2021 - 12/2018
2	Neutropenia 01/2021 - 10/2018
1	Cognitive Dysfunction 04/2024
1	Communicable Diseases (Infectious Diseases) 12/2023
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2023
1	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 01/2023
1	Erdheim-Chester Disease 01/2023
1	Systemic Scleroderma (Systemic Sclerosis) 01/2023
1	Pulmonary Arterial Hypertension 01/2023
1	Leukemia 01/2022
1	Hyperbilirubinemia 11/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021
1	Fatigue 03/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Pain (Aches) 12/2019

Drug/Important Bio-Agent (IBA)

14	Chimeric Antigen ReceptorsIBA 02/2024 - 11/2013
7	tisagenlecleucelIBA 01/2024 - 01/2022
7	axicabtagene ciloleucelIBA 01/2024 - 01/2022
6	Rituximab (Mabthera)FDA Link 03/2024 - 10/2012
5	Histone Deacetylase InhibitorsIBA 09/2023 - 08/2010
5	Azacitidine (5 Azacytidine)FDA Link 08/2023 - 04/2013
5	romidepsin (FK228)FDA Link 01/2017 - 12/2011
3	Brentuximab VedotinIBA 01/2022 - 01/2019
2	Agammaglobulinaemia Tyrosine KinaseIBA 02/2024 - 02/2023
2	Bispecific AntibodiesIBA 01/2024 - 01/2022
2	ibrutinibIBA 10/2023 - 01/2018
2	eltrombopag FDA Link 08/2023 - 12/2018
2	pembrolizumabIBA 01/2022 - 01/2021
2	glofitamabIBA 01/2022 - 12/2021
2	AntigensIBA 12/2021 - 11/2013
2	venetoclaxIBA 11/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 11/2021 - 08/2010
2	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 10/2018
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2018
2	Bortezomib (Velcade)FDA Link 01/2018 - 12/2011
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018 - 12/2011
2	Histones (Histone)IBA 09/2013 - 08/2010
2	PanobinostatIBA 09/2013 - 10/2009
1	Dihydrotachysterol (AT 10)IBA 03/2024
1	VaccinesIBA 12/2023
1	Antiviral Agents (Antivirals)IBA 12/2023
1	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	VemurafenibIBA 01/2023
1	GlucocorticoidsIBA 01/2023
1	Receptor for Advanced Glycation End ProductsIBA 01/2023
1	dabrafenibIBA 01/2023
1	molibresibIBA 01/2023
1	anticentromere antibodyIBA 01/2023
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023
1	Vasodilator Agents (Vasodilators)IBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	AntibodiesIBA 12/2021
1	RO6870810IBA 11/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2021
1	Immune Checkpoint InhibitorsIBA 10/2021
1	Formaldehyde (Formol)FDA Link 10/2021
1	ParaffinIBA 10/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	10-propargyl-10-deazaaminopterin FDA Link 01/2021
1	Prednisolone (Predate)FDA LinkGeneric 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	tazemetostatIBA 11/2020

Therapy/Procedure

39	Therapeutics 01/2024 - 03/2006
12	Drug Therapy (Chemotherapy) 04/2024 - 07/2010
12	Stem Cell Transplantation 11/2023 - 07/2010
3	Immunotherapy 10/2022 - 09/2017
2	Blood Component Removal (Apheresis) 01/2018 - 05/2012
2	Aftercare (After-Treatment) 01/2015 - 08/2012
1	Cognitive Training 04/2024
1	Critical Care (Surgical Intensive Care) 12/2023
1	Time-to-Treatment 12/2023
1	Autologous Transplantation 11/2023
1	Complementary Therapies (Alternative Medicine) 03/2021
1	Tai Ji (Tai Chi Chuan) 03/2021
1	Qigong (Qi Gong) 03/2021
1	Exercise Therapy (Therapy, Exercise) 03/2021
1	Activities of Daily Living (ADL) 12/2019